HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. It has established a service system of "1+2+3+4=1" and can supply D-mannose sourced directly from multiple well-known brand manufacturers.
As a foreign trade enterprise with R&D capabilities, HiSiaddi has repeatedly proposed D-mannose product formulation optimization schemes and application improvement suggestions through technological cooperation with manufacturers and accurate market insight. Below is a technical consulting case of HiSiaddi on D-mannose product formulation optimization.
For more formulation optimization consulting services, please contact HiSiaddi customer service.
The cooperation partner is WellLife Nutrition Inc. based in Vancouver, Canada, a benchmark mid-to-high-end urinary health dietary supplement enterprise on the North American West Coast. Its full product line is sold at premium retail channels including Shoppers Drug Mart high-end health pharmacies across Canada, Wholefood Canada national organic supermarket chains, and offline boutique health stores in Seattle and Portland, USA. The company’s three core terminal products are high-content sustained-release plant capsules, organic ready-to-eat oral powders, and low-temperature oral liquid drops for infants. All products comply with Canada’s NPN Natural Health Product certification, U.S. USP Pharmacopoeia standards, FCC food raw material specifications, and dual USDA Organic & Kosher certifications. It is a high-end client with strict raw material index requirements and refined formulation operations, with stable annual D-mannose procurement of 132 tons divided into three specifications for three independent production lines. The brand previously purchased pharmaceutical-grade D-mannose raw materials from German and Austrian pharmaceutical enterprises in Europe for years. Affected by successive price hikes of overseas raw materials and unstable shipping lead times, the brand launched a localization raw material substitution project from China in 2024.
The client independently selected three domestic manufacturers with D-mannose mass production qualifications and purchased standard national standard grade D-mannose (98.0% purity, universal crushed powder) for its own production lines. Within one month of launch, three major mass production failures occurred: severe caking of oral powders during normal temperature storage, excessive disintegration time of sustained-release capsules failing Canadian pharmaceutical testing, and tiny white crystal precipitation at the bottom of infant low-temperature oral liquids after 30 days of 4℃ refrigeration. The defective rate of finished products surged to 32%, resulting in a large batch of semi-finished product scrappage and direct production losses equivalent to 78,000 Canadian dollars, delaying the new product launch plan by two months. The three domestic raw material manufacturers only supplied finished products per standard specifications, solely controlling national standard purity indicators without internal R&D laboratories for downstream food and dietary preparation formulations. Their technical staff only mastered raw material crystallization production processes and lacked understanding of compatibility rules and production adaptation logic of mannose in capsules, powders, and liquid dosage forms. Multiple minor adjustments to feeding ratios failed to eliminate the failures completely. After seeking help from multiple parties with no resolution, the client entrusted HiSiaddi, a foreign trade service provider specializing in monosaccharide raw materials and application technical support, to fully conduct failure traceability, raw material index rectification, terminal formulation optimization, and production line process adjustment. Relying on HiSiaddi’s cross-industry technical reserves, the technical barrier between raw material manufacturers and formulation producers was bridged.
HiSiaddi formed a special technical team consisting of raw material purification engineers, dietary formulation engineers, and preparation process specialists. The team retrieved original raw material samples, scrapped finished products, and production process records from the client, and conducted full physical and chemical testing with a CNAS-certified third-party laboratory. The root causes of three defective product issues were accurately identified across five dimensions: monomer impurities of raw materials, physical and chemical properties of powder, raw material preparation source, formulation compatibility system, and terminal production parameters, differing from manufacturers’ one-sided conclusion that the client’s formulation ratio was unreasonable.
The pH value of the client’s infant oral liquid formulation was controlled within a weak acid range of 3.4~3.7. After 30 days of constant 4℃ refrigeration storage, abundant needle-shaped white crystals appeared at the bottom of the liquid. Filtration testing confirmed the crystals were mainly D-mannose monomers mixed with trace glucose and fructose impurity sugars. Laboratory testing of the standard D-mannose purchased by the client showed a nominal purity of 98.1% with actual HPLC D-mannose content of 98.02%, including 0.58% glucose impurity and 0.42% fructose impurity, exceeding internal control limits for total impurity sugars under national standards. The standard domestic raw material adopted corn cob enzymatic conversion production with only one-stage ion exchange purification for impurity sugar separation. In a weak acid water environment, impurity sugars disrupted the solubility equilibrium of mannose, and low temperatures triggered premature precipitation of low-solubility impurity sugars accompanied by co-crystallization of partial D-mannose. Residual trace alcohol solvents in raw materials underwent slow hydrolysis catalyzed by organic acids to further exacerbate crystal precipitation, the key factor causing liquid dosage form failure. In addition, standard raw materials lacked low-temperature stability verification data, and manufacturers did not conduct accelerated stability tests targeting acidic liquid systems, an upfront error in raw material selection.
The client’s powder product was a pure single-ingredient D-mannose powder without additional auxiliary materials, packed in aluminum-plastic composite bags for normal temperature sealed storage. The annual average relative humidity in Canadian warehouses ranges from 62% to 70%. Raw materials quickly absorbed moisture and agglomerated during unpacking and mixing feeding; large hard lumps remained even after stirring and mixing, with a caking rate exceeding 40% after 20 days of shelf storage post-packaging. D-mannose is a highly hygroscopic monosaccharide. Standard raw materials are amorphous ultra-fine crushed powder with D50 particle size of only 12 μm, featuring an excessively large specific surface area that easily absorbs water vapor from the environment. Domestic mass production factories adopted universal pulverizers for unified crushing and discharge with no graded particle size control, all raw materials sieved uniformly through 100-mesh screens without regular granulation processes to reduce specific surface area. Meanwhile, the internal control moisture of standard raw materials was 0.35%, exceeding the high-end powder raw material moisture threshold of ≤0.20%. Combined effects of free moisture inherent in raw materials and environmental moisture absorption caused irreversible caking. Simply adjusting the client’s formulation by adding filling auxiliary materials such as corn starch and maltodextrin violated the client’s organic product positioning of "clean label with no extra additives", making simple formulation remediation unfeasible.
Each sustained-release capsule of the client contained 500mg of pure D-mannose powder. Canada’s NPN regulation mandated staged disintegration within 45~60 minutes in artificial gastric fluid and complete dissolution in artificial intestinal fluid. After filling standard raw materials into capsules, capsule disintegration generally exceeded 90 minutes, and all tested samples failed market launch standards. Analysis revealed that standard D-mannose featured disordered crystal forms mixed with particles of varying sizes. Raw materials compacted during filling had excessively low porosity; water entering capsules caused raw materials to absorb moisture and bind into dense hard blocks, hindering water penetration for disintegration. Trace residual inorganic salt impurities in raw materials increased powder adhesion, and raw materials solidified into compact masses under pressure during capsule filling, ultimately extending disintegration time. Mass-produced raw materials lacked crystal form screening and particle size classification and were shipped mixed together, unable to meet the physical property requirements for precise disintegration of sustained-release capsules.
Combined with the client’s organic positioning, regulatory standards, and production line hardware conditions, HiSiaddi adopted a hierarchical remediation scheme prioritizing customized raw material modification, supplemented by minor formulation adjustments, and backed by production parameter optimization. The team coordinated domestic D-mannose manufacturers capable of flexible customized technological transformation to develop exclusive raw material specifications for the three products respectively, supporting terminal formulation and production process optimization, with effect verification completed in three phases: small trial samples, pilot production, and mass production samples.
1. Customized Raw Material Index Rectification: Coordinate manufacturers to upgrade two-stage Simulated Moving Bed (SMB) chromatographic purification sections, adopt beech wood hydrolysis raw materials (to avoid high impurity sugar levels of corn-derived raw materials), produce finished D-mannose with HPLC ≥99.5%, control individual glucose and fructose impurities at 0.09% and 0.07% respectively, and limit total impurity sugars below 0.2%. Extend vacuum solvent removal time in drying sections to reduce methanol and ethanol residues to 50% of USP limits, eliminating substrates for low-temperature crystal precipitation at the source.
2. Minor Formulation Optimization: Add 0.08% food-grade sodium citrate to the original oral liquid formulation to construct a weak acid buffer system, stabilizing minor pH fluctuations and avoiding long-term organic acid catalysis of glycoside hydrolysis. Reduce mannose feeding volume by 5% while maintaining the daily effective intake dose to lower raw material saturation concentration in liquid and reduce oversaturation precipitation risks.
3. Production Process Adjustment: Optimize feeding sequence: fully pre-dissolve D-mannose in 35℃ purified water with low-speed stirring before adding acidic ingredients such as organic acids and fruit & vegetable extracts to prevent local oversaturation crystallization from direct dry powder input into acidic stock solutions. Adopt stepped temperature reduction sterilization post-filling to avoid solute precipitation caused by rapid cooling. Accelerated stability test results: modified samples showed no crystal precipitation after 120 days of constant 4℃ storage, with flavor and physical & chemical indicators fully passing Canadian third-party testing.
1. Upgraded Customized Raw Material Physical Properties: Abandon standard ultra-fine crushed powder; coordinate manufacturers to adopt anhydrous low-temperature spheronization granulation to produce regular spherical particles with D50=280 μm, strictly control raw material moisture ≤0.18%. The entire granulation process excludes auxiliary materials such as maltodextrin and silicon dioxide to meet USDA Organic clean label requirements. The particle repose angle is controlled at 31°, significantly improving powder flowability and reducing specific surface area to mitigate environmental moisture absorption from raw materials.
2. Minor Formulation Adjustment: Adhere to the client’s principle of no extra filling auxiliary materials, only blending 0.05% natural tart cherry powder during packaging. This does not compromise organic certification, and trace fruit acid blocks water vapor adsorption on powder surfaces without altering the core efficacy of mannose.
3. Backend Production Control Optimization: Guide the client to optimize temperature and humidity in Canadian packaging workshops by fixing environmental humidity ≤55%. Raw material unpacking is completed in a closed dehumidified feeding room, and finished products are upgraded to high-barrier aluminum foil vacuum packaging bags to isolate water vapor infiltration from warehouse environments. Test results: modified powders show no caking after 30 days of open storage at normal temperature, and maintain uniform loose powder after 90 days of sealed shelf storage, completely eliminating caking defects.
1. Customized Raw Material Crystal Form & Particle Size Classification: Develop capsule-specific classified crystalline D-mannose with stable α crystal forms, screen out ultra-fine powder and oversized coarse crystals, lock intermediate particle sizes of 80~120 mesh, optimize raw material porosity to facilitate rapid penetration of disintegration liquid, and strictly control ash content of inorganic salts ≤0.03% to eliminate powder adhesion triggers under pressure.
2. Minor Capsule Formulation Adjustment: Maintain the core 500mg mannose content per capsule, add 1.2% organically certified natural rice starch as an internal disintegration auxiliary evenly dispersed in gaps between mannose crystals. The starch rapidly swells upon contact with water to expand raw material agglomerates without compromising the product’s organic qualification.
3. Capsule Filling Production Line Parameter Optimization: Reduce capsule filling machine compression pressure by 15% to avoid dense solidification of raw materials under high pressure, and switch to low-moisture-permeable plant empty capsules to reduce water vapor infiltration into capsules during storage. In vitro disintegration retest results: modified samples achieve an average disintegration time of 52 minutes, fully falling within the qualified range of 45~60 minutes specified by Canada’s NPN regulation, successfully passing official pharmaceutical testing.
HiSiaddi delivered samples in three batches: 500g laboratory samples → 50kg pilot raw materials → 500kg mass production trial raw materials. The client’s Canadian R&D laboratory completed full formulation compatibility tests and accelerated stability tests, followed by three consecutive batches of trial production on its own production lines. The finished product qualification rate of the three products rose from the original 68% to 99.7%, eliminating all scrappage losses. Highly satisfied with HiSiaddi’s complete technical remediation scheme, the client formally signed an annual framework procurement contract of 132 tons with raw material breakdown as follows: 46 tons of high-purity customized raw materials for oral liquids, 52 tons of organic granulated powder raw materials, and 34 tons of classified crystalline raw materials for capsules, scheduled monthly across 14 balanced batches throughout the year.
HiSiaddi’s compliance department assisted manufacturers in sorting supporting documents including Canada NPN raw material filing materials, USP bilingual COA quality inspection reports, USDA Organic traceability documents, and supplementary Kosher certification files, issuing complete customs clearance documents with each shipment to avoid document review risks from Canadian customs and pharmaceutical authorities. Building on this project, the client later entrusted HiSiaddi with all D-mannose procurement and formulation technical services for its Toronto and Montreal subsidiaries, adding an annual procurement volume of 41 tons to raise total annual purchasing capacity to 173 tons.
1. The overall procurement cost of domestically customized D-mannose decreased by 25.7% compared with European imported raw materials, significantly cutting raw material production costs. The three high-end organic products were successfully launched across all Canadian supermarket channels, with terminal retail sales exceeding 1.92 million Canadian dollars in the first launch year. Differentiated product barriers were formed via stable customized raw materials that cannot be easily replicated by competing formulations.
2. Supported by the raw material selection and formulation process knowledge base provided by HiSiaddi, the client refined internal raw material incoming inspection standards. Subsequent procurement of additional monosaccharide raw materials adopted the physical and chemical acceptance indicators formulated by HiSiaddi to avoid repeated mass production failures at the source and reduce future production loss risks.
Cooperating manufacturers refined mass production processes for three segmented product lines: high-purity beech wood mannose, granulated particles, and classified crystalline products through this high-end Canadian customization project, establishing internal raw material control systems aligned with U.S. USP and Canada NPN standards. Relying on this successful project case, the manufacturers subsequently secured fixed supply orders from three mid-to-high-end nutrition brands in the U.S. and Australia, successfully accessing the global high-end pharmaceutical monosaccharide supply chain.
Breaking away from the single business model of traditional foreign trade "only selling raw materials with no technical support", HiSiaddi built a full-link service closed loop covering customized raw material production to backend formulation implementation via integrated raw material purification technology, preparation formulation application, and cross-border regulatory services, forming differentiated core competitiveness and securing stable high-end overseas client resources in the North American high-end monosaccharide raw material foreign trade track.
Most domestic D-mannose manufacturers allocate production capacity to mass-produced standard national standard grade products, with production line equipment, purification processes, and crushing & granulation parameters set for mass popularized production. Enterprise R&D focus centers on increasing raw material crystallization output and reducing costs, generally lacking R&D teams for downstream dietary preparation applications. Manufacturers cannot conduct customized raw material optimization for differentiated dosage forms including capsules, liquids, and powders. Mid-to-high-end organic nutrition brands in Europe, America, and Canada are bound by strict local food regulations and clean label clauses. Minor differences in raw material impurities, particle size, and crystal form directly trigger mass production failures of terminal finished products. When overseas clients independently contact manufacturers, they easily fall into a deadlock of "manufacturers only understand raw material production, clients only understand terminal formulations, with technical information gaps between both sides".
As a neutral foreign trade technical service provider, HiSiaddi connects upstream raw material manufacturers and downstream overseas formulation producers. Supported by full-industry-chain technical reserves to fill information gaps between Chinese and foreign industries, the company systematically resolves mass production failures from three dimensions: raw material index improvement, minor formulation adjustment, and production line optimization. Deep long-term high-end overseas procurement resources are secured via professional technical services, serving as a critical driver for China’s characteristic functional monosaccharide products to enter the global high-end market.
For more formulation optimization consulting services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
